早期乳腺癌确定性单次消融放疗:DESERT-I剂量递增试验方案
DESERT-I是一项前瞻性剂量递增研究,评估早期乳腺癌患者接受确定性单次消融放疗的5个剂量水平(20 Gy、23 Gy、26 Gy、28 Gy、30 Gy),主要目标是确定最大耐受剂量,次要目标包括慢性毒性、生活质量、美容效果、病理和影像学反应及生物标志物分析。
要点
- 入组非小叶浸润性乳腺癌,单灶、ER阳性、HER2阴性、肿瘤<3 cm且腋窝临床阴性。
- 5个剂量队列:20 Gy、23 Gy、26 Gy、28 Gy、30 Gy,主要终点为剂量限制性毒性确定最大耐受剂量。
- 次要终点包括慢性毒性、生活质量、美容效果、6/12个月活检病理反应、12个月影像学反应及生物标志物。
核心结论
- DESERT-I试验旨在确定早期乳腺癌确定性单次消融放疗的最大耐受剂量,为后续II期研究选择安全剂量。
研究设计与样本
- 前瞻性剂量递增研究,设5个剂量队列:20 Gy、23 Gy、26 Gy、28 Gy、30 Gy。
- 入组标准:确诊非小叶浸润性乳腺癌,单灶、雌激素受体阳性、HER2阴性、肿瘤小于3 cm且腋窝临床阴性。
主要发现
- 主要目标为通过评估剂量限制性毒性确定最大耐受剂量。
- 次要目标包括慢性毒性、生活质量、美容效果、治疗6和12个月空心针活检病理反应、治疗12个月MRI或增强乳腺摄影影像学反应。
- 将分析液体活检和肿瘤组织中的生物标志物及肿瘤微环境。
关键数值与推荐
- 5个剂量水平:20 Gy、23 Gy、26 Gy、28 Gy、30 Gy。
- 病理反应评估时间:治疗6和12个月;影像学反应评估时间:治疗12个月。
临床怎么用
- 目前乳腺癌确定性放疗的最佳剂量未知,本试验结果可为后续II期研究确定安全剂量。
- 生物标志物和肿瘤微环境分析可能为患者选择和SABR联合免疫治疗奠定基础。
局限性
- 本文为试验方案,尚未报告剂量递增结果或最大耐受剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a growing trend toward more tolerable and less aggressive treatments for breast cancer patients. For low-risk patients, accelerated partial breast irradiation (APBI) following conservative surgery is a widely used treatment. However, partly due to the development of modern techniques such as stereotactic ablative radiation therapy (SABR), the use of radiotherapy in breast cancer as a neoadjuvant approach has been gaining relevance in recent years. Given the promising results reported in several studies, the use of SABR as a definitive treatment for breast cancer warrants further investigation. The DESERT-I trial is a prospective dose-escalation study designed to evaluate 5 dose levels of definitive single-dose ablative radiotherapy in patients with early-stage breast cancer. METHODS: Eligible patients must have confirmed non-lobular invasive breast cancer that meets the following characteristics: unifocal, estrogen receptor-positive, HER2-negative, tumor size smaller than 3 cm and clinically negative axillary staging. The primary objective of the study is to determine the maximum tolerated dose by assessing dose-limiting toxicity across 5 cohorts: 20 Gy, 23 Gy, 26 Gy, 28 Gy, and 30 Gy. Secondary objectives include evaluating chronic toxicity, quality of life, cosmetic outcomes, pathological response (assessed via core biopsy at 6 and 12 months post-treatment), radiological response (evaluated through MRI or contrast-enhanced mammography at 12 months post-treatment), and analyzing biomarkers and tumor microenvironment in liquid biopsy and tumor tissue. DISCUSSION: The use of definitive radiotherapy in breast cancer remains a largely uncharted area. Currently, the optimal radiation dose required to achieve the best oncological outcome with acceptable toxicity is unknown. The DESERT-I clinical trial aims to determine the maximum tolerated dose across 5 different cohorts, with the goal of using this safe dose in a larger patient population in the phase II study. Additionally, the trial will analyze biomarkers and study tumor microenvironment using both liquid biopsy and tumor tissue. These findings could lay the groundwork for better patient selection and the future combination of SABR with immunotherapy. TRIAL REGISTRATION: This trial was registered on 4th November 2024 with ClinicalTrials.gov Identifier: NCT06671691.
引用
- Gadea-Quinteiro J, Mestre F, Alomar M, et al. Definitive single-fraction ablative radiotherapy for early-stage breast cancer: DESERT-I trial - a dose-escalation study protocol. Radiat Oncol. 2026. PMID: 41521299. doi:10.1186/s13014-025-02735-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。